Search
Lurasidone
go.drugbank.com/drugs/DB08815ApprovedInvestigationalFood and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. … Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S.
Recombinant stabilized RSV A prefusion F antigen
go.drugbank.com/drugs/DB18713ApprovedInvestigationalThe vaccine comprises two antigens - the other being [recombinant stabilized RSV A prefusion F antigen] - which have been expressed in Chinese hamster ovary cell lines and then purified and lyophilized … Recombinant stabilized RSV B prefusion F antigen is one component of a bivalent respiratory syncytial virus (RSV) vaccine called Abrysvo.
Synonyms: RSV subgroup A stabilized prefusion F protein, Recombinant stabilized RSV A prefusion F antigenElivaldogene autotemcel
go.drugbank.com/drugs/DB16746Approved[A243691] ALDP is a key protein that normally breaks down fatty substances in the body called very long-chain fatty acids (VLCFAs). … Elivaldogene autotemcel is a gene therapy consisting of genetically modified autologous cells.
Eflapegrastim
go.drugbank.com/drugs/DB15001ApprovedInvestigationalin which the patient develops an infection during a period of significant neutropenia. … [L43135] In September 2022, eflapegrastim was approved by the US FDA as a prophylactic against infection, as manifested by febrile neutropenia, in patients receiving certain myelosuppressive anti-cancer
Agomelatine
go.drugbank.com/drugs/DB06594ApprovedInvestigationalAgomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression. … In 2006 Servier sold the rights to develop Agomelatine in the US to Novartis. The development for the US market was discontinued in October 2011.
Products: AGOMELATIN AL 25MG FTABromodiphenhydramine
go.drugbank.com/drugs/DB01237ApprovedBromodiphenhydramine is an ethanolamine antihistamine with antimicrobial property. Bromodiphenhydramine is used in the control of cutaneous allergies. … Ethanolamine antihistamines produce marked sedation in most patients.
Synonyms: 2-(p-bromo-α-phenylbenzyloxy)-N,N-dimethylethylamineOnasemnogene abeparvovec
go.drugbank.com/drugs/DB15528ApprovedInvestigationalmuscular atrophy (SMA) and a specific mutation in the survival motor neuron 1 (SMN1) gene. … Developed by AveXis, a Novartis company,[A187253] onasemnogene abeparvovec is commonly marketed as Zolgensma®, which is available as a single-dose intravenous infusion.
Momelotinib
go.drugbank.com/drugs/DB11763ApprovedInvestigationalMomelotinib is a Janus Kinase 1 (JAK1) and 2 (JAK2) inhibitor. It is a competitive inhibitor of JAK ATP binding. … MF includes primary MF (PMF), post-polycythemia vera (PV) MF, and post-essential thrombocythemia (ET) MF. Clinical manifestations of MF include anemia and thrombocytosis.
Synonyms: N-(CYANOMETHYL)-4-(2-(4-MORPHOLINOANILINO)PYRIMIDIN-4-YL)BENZAMIDETinzaparin
go.drugbank.com/drugs/DB06822ApprovedInvestigationalIt is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. … It is an anticoagulant and considered an antithrombotic. Tinzaparin must be given either subcutaneously or parenterally.
Products: .-11700 Anti-XA Iu/ml, INNOHEP 20.000 ANTI XA 0.5Trastuzumab deruxtecan
go.drugbank.com/drugs/DB14962ApprovedInvestigationalTrastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. … [A188988] Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and was first approved by the FDA in 2019.[L10842]